Larvol Delta - Baseline-Characteristics-of-Patients-in-a-Phase-3-Randomized-PlaceboControlled-Trial-of-Admilparant-BMS986278-an-Oral-Lysophosphatidic-Acid-Receptor-1-Antagonist-in-Progressive-Pulmonary-Fibrosis

admilparant (BMS-986278) - BMS

https://acrconvergence2026.eventscribe.net/fsPopup.asp?PresentationID=1897898&mode=presInfo

Fernando j. Martinez, MD

Sep 8, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next